ATE270550T1 - Wirkstoff zum schutz für organ oder gewebe - Google Patents

Wirkstoff zum schutz für organ oder gewebe

Info

Publication number
ATE270550T1
ATE270550T1 AT96908342T AT96908342T ATE270550T1 AT E270550 T1 ATE270550 T1 AT E270550T1 AT 96908342 T AT96908342 T AT 96908342T AT 96908342 T AT96908342 T AT 96908342T AT E270550 T1 ATE270550 T1 AT E270550T1
Authority
AT
Austria
Prior art keywords
group
tissues
active substance
protect organs
organs
Prior art date
Application number
AT96908342T
Other languages
English (en)
Inventor
Mikio Ota
Hideki Horiuchi
Shigehisa Kitahara
Shiro Kondo
Yasuhiro Takano
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13778322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE270550(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Ltd filed Critical Teijin Ltd
Application granted granted Critical
Publication of ATE270550T1 publication Critical patent/ATE270550T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT96908342T 1995-04-07 1996-04-04 Wirkstoff zum schutz für organ oder gewebe ATE270550T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8257695 1995-04-07
PCT/JP1996/000924 WO1996031211A1 (en) 1995-04-07 1996-04-04 Protective agent for organ or tissue

Publications (1)

Publication Number Publication Date
ATE270550T1 true ATE270550T1 (de) 2004-07-15

Family

ID=13778322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96908342T ATE270550T1 (de) 1995-04-07 1996-04-04 Wirkstoff zum schutz für organ oder gewebe

Country Status (11)

Country Link
US (1) US5843969A (de)
EP (1) EP0779074B1 (de)
JP (1) JP3194964B2 (de)
KR (1) KR100308332B1 (de)
AT (1) ATE270550T1 (de)
AU (1) AU703609B2 (de)
CA (1) CA2190993C (de)
DE (1) DE69632854T2 (de)
ES (1) ES2224160T3 (de)
TW (1) TW425284B (de)
WO (1) WO1996031211A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082279A1 (en) * 2002-03-28 2003-10-09 Teijin Limited Solid preparation containing single crystal form
EP1783124A4 (de) * 2004-08-27 2009-07-08 Astellas Pharma Inc 2-phenylthiophenderivat
JP4894517B2 (ja) * 2004-08-27 2012-03-14 アステラス製薬株式会社 ２−フェニルピリジン誘導体
CA2607953A1 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
CN101282934A (zh) 2005-10-07 2008-10-08 安斯泰来制药株式会社 三芳基羧酸衍生物
ATE555810T1 (de) * 2006-02-24 2012-05-15 Astellas Pharma Inc Mittel zur behandlung oder prävention von verdauungsgeschwüren
JP5110536B2 (ja) * 2006-07-19 2012-12-26 学校法人日本医科大学 筋萎縮性側索硬化症治療薬
EP2101761A4 (de) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A Verfahren zur konservierung der nierenfunktion mit xanthin-oxidoreductase-hemmern
PE20170306A1 (es) 2010-06-16 2017-05-06 Takeda Pharmaceuticals Usa Inc Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
AU2011299153B2 (en) 2010-09-10 2014-10-30 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
TW201328692A (zh) * 2011-10-11 2013-07-16 Univ Osaka 脫髓鞘疾病之治療劑及預防劑
EP2692342A1 (de) * 2012-07-30 2014-02-05 Interquim, S.A. Verfahren zur Herstellung pharmazeutischer Zusammensetzungen mit Febuxostat in Tablettenform
CN103848798B (zh) 2012-11-30 2016-01-06 镇江新元素医药科技有限公司 2-芳基硒唑化合物及其药物组合物
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
CA2955577A1 (en) 2014-07-30 2016-02-04 Teijin Pharma Limited Xanthine oxidase inhibitor
HRP20182084T1 (hr) * 2014-07-30 2019-02-08 Teijin Pharma Limited Derivat azol benzena i njegov kristal
PL3176165T3 (pl) 2014-07-30 2019-03-29 Teijin Pharma Limited Kryształ pochodnej azolobenzenowej jako inhibitor oksydazy ksantynowej

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0457803A4 (en) * 1989-02-08 1991-12-04 Abbott Laboratories 4-hydroxythiazoles as 5-lipoxygenase inhibitors
JP2665564B2 (ja) * 1989-08-25 1997-10-22 株式会社大塚製薬工場 細胞防護剤
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
JPH04117371A (ja) * 1990-09-05 1992-04-17 Otsuka Pharmaceut Factory Inc チアゾール誘導体
ES2092580T3 (es) * 1990-11-30 1996-12-01 Teijin Ltd Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
WO1993008820A1 (en) * 1991-10-31 1993-05-13 The Victoria University Of Manchester Treatment of neurological conditions by an interleukin-1 inhibiting compound
JPH05320072A (ja) * 1992-05-20 1993-12-03 Taiho Yakuhin Kogyo Kk 虚血性脳疾患治療薬

Also Published As

Publication number Publication date
EP0779074A1 (de) 1997-06-18
ES2224160T3 (es) 2005-03-01
KR100308332B1 (ko) 2002-09-17
EP0779074B1 (de) 2004-07-07
EP0779074A4 (de) 1999-06-30
DE69632854T2 (de) 2005-07-14
AU5162396A (en) 1996-10-23
DE69632854D1 (de) 2004-08-12
CA2190993A1 (en) 1996-10-10
WO1996031211A1 (en) 1996-10-10
AU703609B2 (en) 1999-03-25
US5843969A (en) 1998-12-01
TW425284B (en) 2001-03-11
JP3194964B2 (ja) 2001-08-06
CA2190993C (en) 2004-06-01

Similar Documents

Publication Publication Date Title
ATE270550T1 (de) Wirkstoff zum schutz für organ oder gewebe
NO970892L (no) Isoksazolderivater
CA2113229A1 (en) Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
ATE232531T1 (de) Heterobizyklische derivate
NO992336L (no) Raf-kinase-inhibitorer
MX9800577A (es) Derivados de 4,5-diaril oxazol.
BG104853A (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
ZA801543B (en) Pharmaceutical heterocyclic compounds and compositions
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
BR1100636A (pt) Agente terapêutico para o mal de parkinson, e, derivado da xantina
WO2001012169A3 (en) Method of cancer treatment
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
IT1196423B (it) Benzotiazolin-composti
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
ATE144768T1 (de) Octahydronaphthalenoxim derivate für die inhibierung der cholesterin biosynthese, ihre herstellung und verwendung
FR2869316A1 (fr) Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
DK0413278T3 (da) Anvendelse af xanthinderivater mod mavesår
DE69532963D1 (de) Verwendung von 4-acylaminopyridin derivaten zur Herstellung eines Medikaments für die Behandlung von zerebrovaskulären Erkrankungen
TH31635A (th) อนุพันธ์คาร์โบไฮเดรต
DE69424677D1 (de) Präparat zur behandlung der drogenabhängigkeit
TH20908B (th) อนุพันธ์คาร์โบไฮเดรต
RU94038051A (ru) Гетероциклические производные, способ их получения, фармацевтическая композиция и способ лечения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0779074

Country of ref document: EP